Keep Me Logged In
The FDA approval of AstraZeneca's new heart disease drug will help it mount a defense against Pfizer's takeover bid -- but it's not really expected to be a blockbuster, CNBC's Catherine Boyle explains.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2018 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by